Home › Supply Chain / Procurement
AAV Supply Chain & Procurement
Raw material sourcing to commercial launch.
End-to-End Solutions
Gene Therapy Supply Chain Complexity
AAV gene therapy supply chains present unique challenges that demand specialized expertise. Limited sourcing options for viral vector manufacturing, extended lead times for specialty raw materials, stringent cold chain requirements, and patient-specific dosing complexities require proactive planning and risk mitigation strategies that pose unique challenge. Our team are experts in navigating the complexities of the ever changing landscape.
We partner with clients to accelerate supplier qualification, secure continuity of supply of long lead time affinity resins, select CDMOs that provide the technical fit with your AAV manufacturing process, and design resilient supply strategies. From academic tech transfer through commercial launch, we provide the supply chain expertise to ensure your gene therapy program maintains reliable material availability.
Viral Vector-Specific Raw Material Sourcing
Specialized procurement capabilities for AAV gene therapy manufacturing materials
Viral vector-specific raw material sourcing including plasmids (Transgene, Rep/Cap, Ad Helper plasmid), media, chromatography resins (AAVX, AVB Sepharose, AEX/CEX resins and monolith technologies), and single use technologies. We manage the entire supplier qualification, quality agreement, and master service agreement negotiations.
Proven Expertise
Our Core Viral Vector Supply Chain Services
Comprehensive procurement and supply chain management services built around the specific requirements of AAV gene therapy and viral vector manufacturing.
Raw Material Planning & Risk Assessment
Bill of materials analysis, safety stock strategy, and AAV-specific critical material qualification
Drug Product Supply Planning
Demand forecasting, capacity planning, and supply chain maps for visibility
Contract Manufacturer (CDMO) Selection for AAV
RFP management, technical due diligence, and CDMO qualification for viral vector manufacturing
Product Storage & Biorepository Management
Cold chain strategy, warehouse management, and 3PL solutions for AAV gene therapy products
Viral Vector Raw Material Risk Framework
Key Material Risk Categories for AAV Manufacturing
Understanding the supply risk profile of your critical starting materials is the foundation of a resilient viral vector supply chain strategy.
| Raw Material | DES Pharma Strategy |
|---|---|
| GMP Plasmids | Early vendor qualification, dual-sourcing, rolling safety stock |
| Cell Culture Media | Lot-to-lot qualification, safety stock, chemically defined alternatives |
| Chromatography Resins | Lifetime studies, resin reuse qualification, alternative resin validation |
| Filtration and Buffer Exchange Consumables | Leachables/extractables qualification, validated alternatives |
| Single-Use Bioprocess Components | In-house generation capability assessment, MCB/WCB backup strategy |
| Excipients & Formulation Components | Standard compendial sourcing with CoA review and supplier qualification |
Our Approach
Tailored Solutions, Immediate Impact
Three core principles that differentiate DES Pharma’s supply chain practice for gene therapy and biologics programs.
Customized Process
We listen, discuss, and understand your program’s specific needs. Our industry knowledge and CDMO network accelerates delivery of a rapid, customized viral vector supply strategy from development to commercialization.
Forward-Thinking Experts
Innovation is embedded in our DNA. Our team of high-performing professionals provides access to the right skills and industry relationships for your program’s specific supply chain needs.
Immediate Value
We create immediate value through robust process implementation, optimizing cost, quality, and supply reliability accelerating your clinical timeline and commercial launch milestones.
Connect With Our Team Today
Build a Resilient Viral Vector Supply Chain Today
Protect your AAV gene therapy program from supply disruptions and CDMO delays.